Technical Analysis for ARNA - Arena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 62.27 1.29% 0.79
ARNA closed up 1.18 percent on Friday, July 12, 2019, on 57 percent of normal volume.

Earnings due: Aug 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARNA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.28%
Inside Day Range Contraction 1.28%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.49%
Multiple of Ten Bullish Other 2.49%
Outside Day Range Expansion 2.49%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.32%
Pocket Pivot Bullish Swing Setup 2.32%
Multiple of Ten Bullish Other 2.32%
Outside Day Range Expansion 2.32%
Multiple of Ten Bullish Other 2.77%

Older signals for ARNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company offers BELVIQ, a drug candidate approved by the United States food and drug administration for chronic weight management in adults. It is also involved in the development of APD811, an agonist of the prostacyclin receptor, which is in Phase I clinical trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor that is in Phase I clinical trials for the treatment of thrombotic diseases. In addition, the company's preclinical development products comprise APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; and GPR119 agonists intended for the treatment of type 2 diabetes. Further, it manufactures drug products under a manufacturing services agreement. The company has a marketing and supply agreement with Ildong Pharmaceutical Co., Ltd. for the commercialization of BELVIQ in South Korea. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Chemistry Health Biopharmaceutical Food Pain Diabetes Medication Autoimmune Diseases Pharmacology Pulmonary Arterial Hypertension Metabolic Diseases Treatment Of Autoimmune Diseases Inflammatory Cannabinoids Chronic Weight Management Manufacturing Services Agreement United States Food And Drug Administration
Is ARNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 62.64
52 Week Low 31.97
Average Volume 559,539
200-Day Moving Average 46.2565
50-Day Moving Average 55.5752
20-Day Moving Average 58.7705
10-Day Moving Average 60.657
Average True Range 1.9596
ADX 24.57
+DI 27.289
-DI 14.9808
Chandelier Exit (Long, 3 ATRs ) 56.7612
Chandelier Exit (Short, 3 ATRs ) 60.5988
Upper Bollinger Band 63.0272
Lower Bollinger Band 54.5138
Percent B (%b) 0.82
BandWidth 14.485839
MACD Line 1.7158
MACD Signal Line 1.661
MACD Histogram 0.0548
Fundamentals Value
Market Cap 2.41 Billion
Num Shares 39.2 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -83.08
Price-to-Sales 8.96
Price-to-Book 12.74
PEG Ratio 0.45
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.93
Resistance 3 (R3) 63.80 62.87 63.52
Resistance 2 (R2) 62.87 62.24 62.93 63.38
Resistance 1 (R1) 62.17 61.86 62.52 62.30 63.25
Pivot Point 61.24 61.24 61.41 61.30 61.24
Support 1 (S1) 60.54 60.61 60.89 60.67 59.71
Support 2 (S2) 59.61 60.23 59.67 59.58
Support 3 (S3) 58.91 59.61 59.44
Support 4 (S4) 59.04